These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8991384)

  • 1. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease.
    Röcken M; Racke M; Shevach EM
    Immunol Today; 1996 May; 17(5):225-31. PubMed ID: 8991384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune deviation strategies in the therapy of psoriasis.
    Ghoreschi K; Röcken M
    Curr Drug Targets Inflamm Allergy; 2004 Jun; 3(2):193-8. PubMed ID: 15180473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells.
    Biedermann T; Mailhammer R; Mai A; Sander C; Ogilvie A; Brombacher F; Maier K; Levine AD; Röcken M
    Eur J Immunol; 2001 May; 31(5):1582-91. PubMed ID: 11465116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.
    Ghoreschi K; Thomas P; Breit S; Dugas M; Mailhammer R; van Eden W; van der Zee R; Biedermann T; Prinz J; Mack M; Mrowietz U; Christophers E; Schlöndorff D; Plewig G; Sander CA; Röcken M
    Nat Med; 2003 Jan; 9(1):40-6. PubMed ID: 12461524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis.
    Mizuguchi J; Takeuchi M; Usui M
    Arch Immunol Ther Exp (Warsz); 2002; 50(4):243-54. PubMed ID: 12371620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.
    Ghoreschi K; Mrowietz U; Röcken M
    J Mol Med (Berl); 2003 Aug; 81(8):471-80. PubMed ID: 12879154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype.
    Afanasyeva M; Wang Y; Kaya Z; Park S; Zilliox MJ; Schofield BH; Hill SL; Rose NR
    Am J Pathol; 2001 Jul; 159(1):193-203. PubMed ID: 11438466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Th1 and Th2 cells in anterior chamber-associated immune deviation.
    Li XY; D'Orazio LT; Niederkorn JY
    Immunology; 1996 Sep; 89(1):34-40. PubMed ID: 8911137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease.
    Racke MK; Bonomo A; Scott DE; Cannella B; Levine A; Raine CS; Shevach EM; Röcken M
    J Exp Med; 1994 Nov; 180(5):1961-6. PubMed ID: 7525845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy.
    Min B; Legge KL; Pack C; Zaghouani H
    J Exp Med; 1998 Dec; 188(11):2007-17. PubMed ID: 9841915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon-gamma, the Th1/Th2 paradigm and autoimmune diseases].
    Billiau A
    Verh K Acad Geneeskd Belg; 1998; 60(4):271-85. PubMed ID: 9883078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early delayed-type hypersensitivity eosinophil infiltrates depend on T helper 2 cytokines and interferon-gamma via CXCR3 chemokines.
    Akahira-Azuma M; Szczepanik M; Tsuji RF; Campos RA; Itakura A; Mobini N; McNiff J; Kawikova I; Lu B; Gerard C; Pober JS; Askenase PW
    Immunology; 2004 Mar; 111(3):306-17. PubMed ID: 15009431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
    Xu H; Rizzo LV; Silver PB; Caspi RR
    Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synovial fluid T cells from patients with rheumatoid arthritis are refractory to the T helper type 2 differentiation-inducing effects of interleukin-4.
    Isomäki P; Luukkainen R; Lassila O; Toivanen P; Punnonen J
    Immunology; 1999 Mar; 96(3):358-64. PubMed ID: 10233716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?
    Martin R
    Trends Pharmacol Sci; 2003 Dec; 24(12):613-6. PubMed ID: 14654299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro- and anti-inflammatory effects of IL-4: from studies in mice to therapy of autoimmune diseases in humans.
    Biedermann T; Röcken M
    Ernst Schering Res Found Workshop; 2005; (50):235-42. PubMed ID: 15526946
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th1-response.
    Häggqvist B; Hultman P
    Clin Exp Immunol; 2003 Nov; 134(2):202-9. PubMed ID: 14616778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-10 has a protective role in experimental autoimmune uveoretinitis.
    Rizzo LV; Xu H; Chan CC; Wiggert B; Caspi RR
    Int Immunol; 1998 Jun; 10(6):807-14. PubMed ID: 9678762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo.
    Powrie F; Menon S; Coffman RL
    Eur J Immunol; 1993 Sep; 23(9):2223-9. PubMed ID: 8370402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo.
    Powrie F; Menon S; Coffman RL
    Eur J Immunol; 1993 Nov; 23(11):3043-9. PubMed ID: 8223881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.